ATE362771T1 - Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat - Google Patents

Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat

Info

Publication number
ATE362771T1
ATE362771T1 AT03706732T AT03706732T ATE362771T1 AT E362771 T1 ATE362771 T1 AT E362771T1 AT 03706732 T AT03706732 T AT 03706732T AT 03706732 T AT03706732 T AT 03706732T AT E362771 T1 ATE362771 T1 AT E362771T1
Authority
AT
Austria
Prior art keywords
iressa
pharmaceutical
water
composition containing
cellulose derivative
Prior art date
Application number
AT03706732T
Other languages
English (en)
Inventor
Paul Richard Gellert
Michael Davis Parker
Matas Marcel De
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE362771(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE362771T1 publication Critical patent/ATE362771T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03706732T 2002-02-26 2003-02-24 Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat ATE362771T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE362771T1 true ATE362771T1 (de) 2007-06-15

Family

ID=27767732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03706732T ATE362771T1 (de) 2002-02-26 2003-02-24 Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat

Country Status (29)

Country Link
US (2) US20050163835A1 (de)
EP (1) EP1480679B1 (de)
JP (1) JP4544863B2 (de)
KR (2) KR20100090726A (de)
CN (1) CN1326569C (de)
AR (1) AR038848A1 (de)
AT (1) ATE362771T1 (de)
AU (1) AU2003208444B2 (de)
BR (1) BRPI0307786B8 (de)
CA (1) CA2476587C (de)
CO (1) CO5601038A2 (de)
CY (1) CY1108026T1 (de)
DE (1) DE60313956T2 (de)
DK (1) DK1480679T3 (de)
ES (1) ES2286406T3 (de)
IL (2) IL163642A0 (de)
IS (1) IS2462B (de)
MX (1) MXPA04008307A (de)
MY (1) MY135609A (de)
NO (1) NO328658B1 (de)
NZ (1) NZ534513A (de)
PL (1) PL208114B1 (de)
PT (1) PT1480679E (de)
RU (1) RU2318518C2 (de)
SA (1) SA03240043B1 (de)
TW (1) TWI271193B (de)
UA (1) UA76325C2 (de)
UY (1) UY27682A1 (de)
WO (1) WO2003072139A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480650B1 (de) 2002-02-26 2010-04-28 AstraZeneca AB Neue kristalline formen der krebsbekämpfenden verbindung zd1839
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
US20100168410A1 (en) 2006-10-27 2010-07-01 Pfizer Products Inc. Hydroxypropyl Methyl Cellulose Hard Capsules and Process of Manufacture
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
CA2766067A1 (en) * 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
JP5779591B2 (ja) * 2009-12-22 2015-09-16 アッヴィ・インコーポレイテッド Ａｂｔ−２６３カプセル剤
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
CA2811805A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SG190399A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Methods of treatment using selective bcl-2 inhibitors
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
CN107266435A (zh) 2010-11-23 2017-10-20 Abbvie 公司 细胞凋亡诱导剂的盐和晶形
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
SMT202200255T1 (it) 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
EP3233064A1 (de) 2014-12-19 2017-10-25 Synthon BV Pharmazeutische zusammensetzung mit gefifinib
FI4233847T3 (fi) * 2015-02-26 2024-09-24 Takeda Pharmaceuticals Co Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
JP6739289B2 (ja) * 2016-08-25 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬錠剤の製造方法
DK3518932T3 (da) 2016-09-30 2025-01-27 Takeda Pharmaceuticals Co Behandling af prostatacancer
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法
MX2022015003A (es) 2020-05-29 2023-03-03 Myovant Sciences Gmbh Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
WO1995006462A1 (en) * 1993-08-30 1995-03-09 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1175205B1 (de) * 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
EP1480650B1 (de) * 2002-02-26 2010-04-28 AstraZeneca AB Neue kristalline formen der krebsbekämpfenden verbindung zd1839
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
CA2476587C (en) 2010-05-04
WO2003072139A1 (en) 2003-09-04
KR20100090726A (ko) 2010-08-16
JP4544863B2 (ja) 2010-09-15
MXPA04008307A (es) 2004-11-26
PT1480679E (pt) 2007-07-18
NZ534513A (en) 2007-04-27
NO20043866L (no) 2004-09-15
DK1480679T3 (da) 2007-09-03
TW200304379A (en) 2003-10-01
EP1480679A1 (de) 2004-12-01
EP1480679B1 (de) 2007-05-23
MY135609A (en) 2008-05-30
CO5601038A2 (es) 2006-01-31
CN1326569C (zh) 2007-07-18
SA03240043B1 (ar) 2007-05-06
BRPI0307786B8 (pt) 2021-05-25
CN1638805A (zh) 2005-07-13
RU2318518C2 (ru) 2008-03-10
PL372215A1 (en) 2005-07-11
AU2003208444B2 (en) 2006-10-26
UA76325C2 (uk) 2006-07-17
DE60313956T2 (de) 2008-05-15
RU2004129280A (ru) 2005-06-10
IL163642A0 (en) 2005-12-18
IS7420A (is) 2004-08-24
BRPI0307786B1 (pt) 2018-03-13
KR20040088524A (ko) 2004-10-16
US20050163835A1 (en) 2005-07-28
TWI271193B (en) 2007-01-21
KR101002374B1 (ko) 2010-12-17
CY1108026T1 (el) 2013-09-04
AR038848A1 (es) 2005-01-26
ES2286406T3 (es) 2007-12-01
IS2462B (is) 2008-11-15
CA2476587A1 (en) 2003-09-04
NO328658B1 (no) 2010-04-19
AU2003208444A1 (en) 2003-09-09
HK1070585A1 (en) 2005-06-24
JP2005523293A (ja) 2005-08-04
IL163642A (en) 2007-07-24
UY27682A1 (es) 2003-10-31
PL208114B1 (pl) 2011-03-31
US20090186890A1 (en) 2009-07-23
BR0307786A (pt) 2004-12-07
DE60313956D1 (de) 2007-07-05

Similar Documents

Publication Publication Date Title
ATE362771T1 (de) Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat
DE60307677D1 (de) Dispergierbare pharmazeutische zusammensetzungen
DE60142197D1 (de) Pharmazeutische Zusammensetzung
ATE380544T1 (de) Umhüllte feste darreichungsform
ATE404180T1 (de) Geschmacksmaskierte pharmazeutische partikel
DE60315939D1 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
FIU20060387U0 (fi) Lantaaniyhdisteitä käsittävä farmaseuttinen koostumus
EP1748765A4 (de) Pharmazeutische suspensionszusammensetzung
DK1615646T4 (da) Farmaceutiske formuleringer, der indeholder methylnaltrexon
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
ATE367152T1 (de) Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
DE60304599D1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
ATE327759T1 (de) Pharmazeutische zusammensetzung mit verlungerter freisetzung
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE337317T1 (de) Imidazopyrin-derivate, verfahren zu ihrer herstellung and sie enthaltende pharmazeutische zusamensetzungen
ATE366128T1 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
DE602005003453D1 (de) Neue effektor-konjugate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
IS7581A (is) Lyfjasamsetning
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1480679

Country of ref document: EP